Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05143125
Other study ID # HEM-ONCO-009
Secondary ID
Status Recruiting
Phase Phase 1/Phase 2
First received
Last updated
Start date February 5, 2021
Est. completion date February 2024

Study information

Verified date February 2021
Source Shenzhen University General Hospital
Contact Li Yu, Dr
Phone +8675521839178
Email liyu@vip.163.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Natural killer cells (NK cells) are derived from bone marrow lymphoid stem cells, which are a type of lymphocytes that can non-specifically kill tumor cells and virus-infected cells without pre-sensitization. NK cells can not only directly kill malignant diseased cells, but also participate in the regulation of immune cell response and play a role in a variety of tumor immunotherapy strategies. The 2-year survival rate of NK cells combined with stem cell therapy for patients with hematological malignancies reached 36%, which is significantly higher than the 2-year survival rate (about 15%) of stem cell therapy alone, which can extend the disease-free survival period of leukemia patients by an average of 1.5 years. Relapsed and refractory leukemia can achieve a complete remission rate of up to 40%.


Description:

Natural killer cells (NK cells) are derived from bone marrow lymphoid stem cells, which are a type of lymphocytes that can non-specifically kill tumor cells and virus-infected cells without pre-sensitization. NK cells can not only directly kill malignant diseased cells, but also participate in the regulation of immune cell response and play a role in a variety of tumor immunotherapy strategies. The 2-year survival rate of NK cells combined with stem cell therapy for patients with hematological malignancies reached 36%, which is significantly higher than the 2-year survival rate (about 15%) of stem cell therapy alone, which can extend the disease-free survival period of leukemia patients by an average of 1.5 years. Relapsed and refractory leukemia can achieve a complete remission rate of up to 40%. However, NK cell therapy alone or the use of autologous NK cells to treat solid tumors is not effective. In clinical trials related to rectal cancer, esophageal cancer, kidney cancer, and gastric cancer, the clinical response of NK cell adoptive therapy is not good. A phase II clinical study found that the disease control rate of patients with ovarian cancer and breast cancer after radiotherapy and chemotherapy can reach about 60% by NK cell infusion. The main reason for the low treatment efficiency of solid tumors is related to the immunosuppressive effect of the tumor microenvironment. Combination therapy is a potential breakthrough. Researches targeting tumor immune microenvironment, targeting tumor cells and combined with NK cell therapy have shown tumor therapeutic potential. NK cells combined with IgG1 antibody treatment of gastric cancer and colon cancer in about 50% of patients with partial remission, and 17% of patients are in stable condition. In summary, the combined application of the demethylation drug DAC and NK cell infusion may be a new clinical strategy for the treatment of malignant tumors.


Recruitment information / eligibility

Status Recruiting
Enrollment 60
Est. completion date February 2024
Est. primary completion date February 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria: 1. Male or female patients aged 18-70 (including 18 and 70 years old); 2. Those who have been diagnosed as malignant tumor by pathological and histological examination, have received anti-tumor treatment and are in remission; 3. The ECOG score of the patient is less than 2 points; 4. The patient did not receive any chemotherapy, radiotherapy, immunotherapy (such as immunosuppressive drugs) and other anti-tumor treatments within 4 weeks before enrollment, and his previous treatment-related toxicity had returned to grade <1 (hair loss, peripheral nerves) at the time of enrollment Except for low-level toxicity such as inflammation); 5. The patient's intravenous access is unobstructed, which can meet the needs of intravenous drip; 6. The patient voluntarily participates and signs an informed consent form, and follows the research treatment plan and visit plan. Exclusion Criteria: 1. The patients used high-dose hormones within 1 week before enrollment (except for patients using inhaled hormones); 2. People with severe autoimmune diseases, immunodeficiency diseases or severe allergies; 3. Patients who have been treated with other cellular immune products (DC, T, CTL, CAR-T, etc.); 4. The patient had an uncontrollable infection within 4 weeks before enrollment; 5. Active B HBV DNA>1000copy/mL/C virus hepatitis (anti-HCV positive, HCV RNA positive), HIV positive, syphilis positive; 6. The patient has participated in other clinical studies within 6 weeks before enrollment; 7. Patients suffering from mental illness; 8. The patient has drug abuse/addiction and medical, psychological or social conditions that may interfere with research or have an impact on the evaluation of research results; 9. The patient has alcohol dependence; 10. Women who are pregnant (positive urine/blood pregnancy studies) or breastfeeding; men or women who have a pregnancy plan within the past year; patients cannot be guaranteed to take effective contraceptive measures during the study period; 11. According to the judgment of the investigator, the patient has other conditions that are not suitable for enrollment.

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
Decitabine combined with NK cell infusion
Decitabine combined with NK cell infusion

Locations

Country Name City State
China Shenzhen University General hospital Shenzhen Guangdong

Sponsors (1)

Lead Sponsor Collaborator
Shenzhen University General Hospital

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Disease-free survival DFS From date of initial treatment to the end of follow up, up to 2 years
Secondary Overall survival rate OS From admission to the end of follow up, up to 2 years.
See also
  Status Clinical Trial Phase
Recruiting NCT05640115 - Obstruction of Malignancy: Percutaneous Renal vs Endoscopic Stent Early Phase 1
Recruiting NCT02891642 - Liquid Biopsy With Immunomagnetic Beads Capture Technique for Malignant Cell Detection in Body Fluid
Completed NCT02282449 - Power Injectable Versus a Non-Power Injectable, Upper Arm, TIVAD for Chemotherapy N/A
Completed NCT01212731 - Skull Base and Low Grade Glioma Neurocognitive Magnetic Resonance Imaging (MRI) Study
Completed NCT01199822 - Study of the Safety and Pharmacokinetics of IMC-3G3 in Japanese Patients With Solid Tumors Phase 1
Recruiting NCT04122469 - The Role of Stereo-tActic BoDy RadIotherApy iN Oligo-Progressive MalignanT Disease N/A
Recruiting NCT03561727 - Risk Factors for Development of Incisional Hernia in Transverse Incisions N/A
Terminated NCT03251924 - A Dose Escalation and Combination Immunotherapy Study to Evaluate BMS-986226 Alone or in Combination With Nivolumab or Ipilimumab in Patients With Advanced Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT03997968 - A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT00092222 - Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity Phase 2
Recruiting NCT05770102 - DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Teenage/Young Adults and Paediatric Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition Phase 2/Phase 3
Recruiting NCT05886764 - Novel Outreach Methods to Increase Enrollment to Early Phase Clinical Trials N/A
Not yet recruiting NCT05992363 - Tandem Polyurethane Stents Compared to Single Silicone Stent for Malignant Ureteral Obstruction Phase 3
Recruiting NCT05761366 - Application of 18F-PSMA PET / CT Imaging in Prostate Specific Membrane Antigen Positive Tumor Phase 2
Recruiting NCT04887545 - Immune- and Microenvironment- Proteogenomics Profiling for Classifying Lung Cancer Patients
Completed NCT03061955 - Safety and Efficacy of Concurrent Administration of Influenza Vaccine in Patients Undergoing Anti-PD-1 Immunotherapy (Nivolumab, Pembrolizumab)
Completed NCT03909464 - Non-Invasive Neurosensory Testing For Chemotherapy-Induced Peripheral Neuropathy
Active, not recruiting NCT02649491 - Using an Electronic Nose to Predict Gastrointestinal Consequences of Pelvic Radiotherapy N/A
Recruiting NCT02776995 - Tumor Monitoring Using Thermography During Radiation Therapy N/A
Active, not recruiting NCT01242072 - Intravenous Palifosfamide-tris in Combination With Etoposide and Carboplatin in Patients With Malignancies Phase 1